Conversely, raloxifene, an FDA-approved second-generation SERM, although estrogenic in its reduction of the severity of postmenopausal osteoporosis, is, broadly speaking, antiestrogenic in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback